• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 13, 2017

View Archived Issues

Shop 'til you stop: Immunomedics' $2B tie-up with Seattle Genetics offers escape hatch

In order to go it alone with antibody drug conjugate (ADC) IMMU-132, Immunomedics Inc. would need to immediately raise $150 million to cover the phase III trial in triple-negative breast cancer (TNBC) and another $125 million to build a sales force, which is one reason why the company signed a potential $2 billion deal with Seattle Genetics Inc. focused on the drug more specifically known as sacituzumab govitecan, said Jason Aryeh, vice chairman of the board and chairman of the transaction committee. Read More

Bench Press: BioWorld looks at translational medicine

In type I diabetes, most insulin-producing pancreatic beta cells are destroyed by an autoimmune reaction. But, researchers from Yale University have discovered, the beta cells do not take that attack without countering, and over the course of type I diabetes development, some pancreatic beta cells can develop resistance to autoimmune attack. Read More

'Marathon' effort leads to quick approval for Emflaza in DMD

Marathon Pharmaceuticals LLC sped Emflaza (deflazacort) through development to treat Duchenne muscular dystrophy (DMD) in patients 5 and older, gaining FDA approval just six years after the company was formed. Read More

'Dream investor' Novo bolsters Evotec's coffers with €90.3M

LONDON – Evotec AG is bolstering its coffers by €90.3 million (US$96.1 million) in a private placing of new shares with Novo A/S, and plans to invest the funds to further develop its induced pluripotent stem cell (iPSC) platform, pursue M&A opportunities and provide long-term support to its early stage drug discovery partnerships. Read More

TRC105 fails to extend Avastin's PFS benefit in glioblastoma study

Tracon Pharmaceuticals Inc. reported that adding its lead candidate, TRC105 (carotuximab), to Avastin (bevacizumab) didn't appear to help patients with recurrent glioblastoma enjoy any more time without a worsening of their condition than Avastin monotherapy does. Read More

Pharma chiefs: India must shift focus from manufacturing to design

HYDERABAD – India is registering healthy growth in pharma exports that are expected increase between 8 percent and 10 percent this year and the next, according to government estimates. It's powered by the country's strength as a generics manufacturing hub. Read More

'Bioinspired' culturing process loses serum, gains reproducibility

Serum – the part of blood that is left over after red cells are removed – is a cornerstone of cell culture. Fetal bovine serum, with its mix of growth factors and nutrients, certainly enables cultured cells to grow. Read More

Financings

Santhera Pharmaceuticals AG, of Liestal, Switzerland, said it placed CHF60 million (US$59.7 million) senior unsecured convertible bonds due 2022. Read More

Other news to note

Catalyst Biosciences Inc., of South San Francisco, disclosed a reverse stock split of its shares of common stock at a ratio of 1-for-15, effective Friday. Shares will begin trading on a split-adjusted basis on Monday, and the number of shares of Catalyst's common stock outstanding will decrease from about 13 million pre-split shares to about 868,000 post-split shares. Read More

In the clinic

Cellceutix Corp., of Beverly, Mass., has initiated its main clinical site for a phase IIa trial of the p53 activator Kevetrin (thioureidobutyronitrile) in the treatment of platinum-resistant/refractory ovarian cancer. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe